North America’s medical devices industry saw a rise of 10.11% in deal activity during March 2021, when compared with the last 12-month average, led by Hellman & Friedman’s $1bn acquisition of Cardinal Health, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 98 medical devices industry deals worth $4.89bn were announced for the region in March 2021, against the 12-month average of 89 deals.
Of all the deal types, venture financing saw most activity in March 2021 with 64 transactions, representing a 65.3% share for the region.
In second place was M&A with 26 deals, followed by private equity deals with eight transactions, respectively capturing a 26.5% and 8.2% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $2.41bn, while venture financing and private equity deals totalled $1.3bn and $1.18bn, respectively.
North America medical devices industry deals in March 2021: Top deals
The top five medical devices deals accounted for 55.8% of the overall value during March 2021.
The combined value of the top five medical devices deals stood at $2.73bn, against the overall value of $4.89bn recorded for the month.
The top five medical devices industry deals of March 2021 tracked by GlobalData were:
1) Hellman & Friedman’s $1bn private equity deal with Cardinal Health
2) The $695m acquisition deal with Resolution Bioscience by Agilent Technologies
3) Agiliti’s $475m acquisition of Northfield Medical
4) The $320m acquisition of Asuragen by Bio Techne
5) Organon &’s acquisition of Alydia Health for $240m.